Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:42 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer vaccine, showing improved recurrence-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:37 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:32 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. The stock surged 177%, a record one-day gain, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:27 PM UTC

Segments 13-16 describe Moderna's successful Phase 3 cancer vaccine trial, which led to a 177% stock surge. This is a material positive catalyst indicating improved expected fundamentals for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:22 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:17 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients going longer without cancer recurrence, and Moderna shares closing 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:12 PM UTC

Segments 13-17 report that Moderna's personalized cancer treatment succeeded in a Phase 3 trial, leading to a 177% stock increase. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:07 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, demonstrating improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:02 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, with shares surging 177%. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:57 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda showing longer recurrence-free survival than Keytruda alone, leading to a 177% stock increase. This is a material positive catalyst for the company.